A Phase 3 interventional study of Follicle Stimulating Hormone and Follicle Stimulating Hormone in Infertility, sponsored by IBSA Institut Biochimique SA. Completed at 7 sites in 2 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2015-03-27.
Sponsored by IBSA Institut Biochimique SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Follicle Stimulating Hormone in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Follicle Stimulating Hormone · Infertility.
Among the 12 studies testing Follicle Stimulating Hormone in Infertility, this one is the 9th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 3, and was the 1st registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 12 studies testing Follicle Stimulating Hormone in Infertility is open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 19–37 · Women only · Healthy volunteers
By country, each count listing its studies:
Follicle Stimulating Hormone: first FDA approval 1997 (GONAL-F). What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 239 across the 12 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 10 most frequent:
IBSA Institut Biochimique SA is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
13 studies in Infertility by IBSA Institut Biochimique SA: none open now, none under way, none of them phase 3. Of 12 finished, 3 (25%) have results posted.
Among the 13 studies in Infertility by IBSA Institut Biochimique SA, this one is the 8th largest by enrollment, is the only one that started in 2003, is one of 8 in phase 3, and was the 1st registered.
IBSA Institut Biochimique SA’s Infertility studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Follicle Stimulating Hormone in Infertility, from their registry updates:
Among IBSA Institut Biochimique SA’s 13 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Serono) when administered in patients undergoing ICSI
This is a multicentric, prospective, randomised, investigator blind, controlled clinical trial (phase III) of two parallel groups, one receiving the test drug FSH (Fostimon® , IBSA) and the other the reference drug FSH (Gonal-F®, Serono). The groups will be paired on the major prognostic criteria.
In effect, a double blind trial is not really feasible since the drugs presentations are very different. However, in IVF, drugs are usually dispensed and/or injected by a nurse and therefor the Investigator can be blind. Moreover, the used preparations will contain the same amount of gonadotrophin units (75 IU), will be repackaged in anonymous boxes and the following sentence will be written in the Patient Information Sheet: "You are required not to inform the Investigator about the product's name".
The randomisation is necessary to get groups as comparable as possible for all the other aspects. The multicentric design has the double interest of facilitating the patients' recruitment and of decreasing the biases related to attitudes in a specific centre.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women undergoing ovarian stimulation for IntraCytoplasmic Sperm Injection (ICSI) with the following characteristics:
>/= 18 and \< 40 years old between 19 and 30 kg/m2 less than 3 previous completed cycles basal FSH level less than 10 IU/l within the 6 months prior to the study
Exclusion Criteria:
age \< 18 and >/= 40 years primary ovarian failure or women known as poor responders, i.e. requiring more than 225 IU of FSH as starting dose in previous treatment cycles or having less than 3 oocytes retrieved or with an oestradiol serum concentration \< 900 pmol/l (250 pg/ml) ovarian cysts > 20 mm oocyte donation thawed embryos replacement patients affected by pathologies associated with any of being pregnant ascertained or presumptive to the active principle and/or their ingredients abnormal bleeding of undetermined origin uncontrolled thyroid or adrenal dysfunction neoplasias severe impairment of the renal and/or hepatic functions women deprived of their freedom by administrative or legal decision
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fostimon is an highly purified FSH preparation.
Drug: Follicle Stimulating Hormone
Gonal-F is a recombinant FSH preparation.
Drug: Follicle Stimulating Hormone
subcutaneous injection of FSH. Starting dose: 225 IU.
Also known as: highly purified human derived FSH; Fostimon
subcutaneous injection of FSH. Starting dose: 225 IU.
Also known as: rec FSH; Gonal F
Total Number of Oocytes Retrieved
Total number of oocytes retrieved
Time frame: 10 days after stimulation start
Clinical Pregnancy Rate
clinical pregnancy rate defined as the presence of gestation sac and heart beat.
Time frame: 6 weeks after treatment start
| Milestone | Fostimon | Gonal-f |
|---|---|---|
| Started | 75 | 76 |
| Completed | 71 | 71 |
| Not completed | 4 | 5 |
Total number of oocytes retrieved
| oocytes | Fostimon | Gonal-f |
|---|---|---|
| Total Number of Oocytes Retrieved | 10.9 ± 4.9 | 12.0 ± 5.6 |
clinical pregnancy rate defined as the presence of gestation sac and heart beat.
| percentage of treated patients | Fostimon | Gonal-F |
|---|---|---|
| Clinical Pregnancy Rate | 30.1 | 29.2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fostimon | — | 2/73 (2.7%) | 3/73 (4.1%) |
| Gonal-F | — | 5/72 (6.9%) | 3/72 (4.2%) |
| Event | Fostimon | Gonal-F |
|---|---|---|
| OHSSPregnancy, puerperium and perinatal conditions | 1/73 | 4/72 |
| Spontaneous abortionPregnancy, puerperium and perinatal conditions | 0/73 | 1/72 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/73 | 0/72 |
| Event | Fostimon | Gonal-F |
|---|---|---|
| Ovarian cystPregnancy, puerperium and perinatal conditions | 2/73 | 1/72 |
| spontaneous abortionPregnancy, puerperium and perinatal conditions | 1/73 | 1/72 |
| tirednessGeneral disorders | 0/73 | 1/72 |
| Age, Continuous(years) | Fostimon | Gonal-f | Total |
|---|---|---|---|
| Mean | 29.9 ± 4.0 | 30.0 ± 3.6 | 30.0 ± 3.8 |
| Sex: Female, Male(Participants) | Fostimon | Gonal-f | Total |
|---|---|---|---|
| Female | 75 | 76 | 151 |
| Male | 0 | 0 | 0 |
| basal FSH(IU/L) | Fostimon | Gonal-f | Total |
|---|---|---|---|
| Mean | 5.9 ± 2.5 | 6.0 ± 1.9 | 6.0 ± 2.2 |
The record gives a start of Mar 2003, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 9 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follicle Stimulating Hormone
IBSA Institut Biochimique SA →